
Akers Biosciences, Inc. AKER
Akers Biosciences, Inc. Financial Ratios 2011-2026 | AKER
Annual Financial Ratios Akers Biosciences, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-0.0 | -0.2 | -0.6 | -0.2 | -1.0 | -0.3 | -2.6 | -2.7 | - | - |
P/S |
- | 0.6 | 3.8 | 0.3 | 1.1 | 1.5 | 1.8 | 1.2 | - | - |
EV/EBITDA |
-0.0 | -0.1 | -0.7 | -0.2 | -0.7 | -0.4 | -2.6 | -2.6 | - | - |
PEG |
-0.0 | -0.0 | -0.01 | 0.0 | -0.01 | 0.0 | -0.08 | -0.07 | - | - |
P/B |
0.0 | 0.1 | 1.1 | 0.1 | 1.0 | 0.5 | 0.5 | 1.0 | - | - |
P/CF |
-0.1 | -0.3 | -0.7 | -0.2 | -0.8 | -0.6 | -2.0 | -1.5 | - | - |
ROE % |
-50.84 | -41.56 | -185.97 | -63.70 | -97.52 | -141.02 | -21.12 | -37.04 | - | - |
ROA % |
-161.51 | -35.72 | -138.96 | -53.32 | -64.96 | -112.57 | -18.78 | -25.13 | - | - |
ROCE % |
-131.33 | -40.67 | -146.65 | -55.44 | -136.62 | -106.80 | -21.64 | -43.93 | - | - |
DSO |
- | 9.9 | 38.6 | 150.1 | 78.1 | 127.1 | 191.8 | 211.9 | - | - |
DIO |
- | 66.1 | 138.9 | 474.3 | 686.3 | 434.4 | 281.1 | 195.5 | - | - |
DPO |
- | 218.4 | 162.9 | 254.2 | 372.5 | 206.7 | 113.1 | 118.8 | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Akers Biosciences, Inc., allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
The Cooper Companies
COO
|
$ 70.29 | 0.17 % | $ 14 B | ||
|
Atrion Corporation
ATRI
|
- | - | $ 810 M | ||
|
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | ||
|
Alcon
ALC
|
$ 74.63 | 0.09 % | $ 40.4 B | ||
|
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | ||
|
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | ||
|
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | ||
|
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | ||
|
Baxter International
BAX
|
$ 16.65 | -0.18 % | $ 8.54 B | ||
|
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | ||
|
BioLife Solutions
BLFS
|
$ 19.27 | -1.23 % | $ 888 M | ||
|
AtriCure
ATRC
|
$ 29.19 | 0.41 % | $ 1.39 B | ||
|
electroCore
ECOR
|
$ 7.04 | 3.53 % | $ 59.7 K | ||
|
Ekso Bionics Holdings
EKSO
|
$ 9.75 | 3.72 % | $ 23.7 M | ||
|
Glaukos Corporation
GKOS
|
$ 116.69 | 3.48 % | $ 5.65 B | ||
|
Haemonetics Corporation
HAE
|
$ 58.46 | 2.87 % | $ 2.94 B | ||
|
Harvard Bioscience
HBIO
|
$ 5.53 | 6.35 % | $ 245 M | ||
|
ICU Medical
ICUI
|
$ 122.99 | -0.26 % | $ 3.03 B | ||
|
InfuSystem Holdings
INFU
|
$ 9.43 | 1.51 % | $ 195 M | ||
|
iRhythm Technologies
IRTC
|
$ 117.22 | 0.36 % | $ 3.75 B | ||
|
Isoray
ISR
|
- | 0.03 % | $ 108 M | ||
|
Intuitive Surgical
ISRG
|
$ 452.58 | 0.11 % | $ 162 B | ||
|
Repro Med Systems
KRMD
|
$ 4.26 | -1.39 % | $ 197 M | ||
|
LeMaitre Vascular
LMAT
|
$ 109.16 | 0.62 % | $ 2.47 B | ||
|
Masimo Corporation
MASI
|
$ 178.49 | -0.06 % | $ 9.51 B | ||
|
Microbot Medical
MBOT
|
$ 2.36 | -1.67 % | $ 108 M | ||
|
Milestone Scientific
MLSS
|
$ 0.29 | 1.9 % | $ 23.8 M | ||
|
Merit Medical Systems
MMSI
|
$ 67.81 | 0.16 % | $ 4.01 B | ||
|
Envista Holdings Corporation
NVST
|
$ 25.81 | - | $ 4.34 B | ||
|
Predictive Oncology
POAI
|
- | - | $ 31.1 M | ||
|
Pro-Dex
PDEX
|
$ 48.53 | -6.08 % | $ 160 M | ||
|
Pulse Biosciences
PLSE
|
$ 22.94 | -0.26 % | $ 1.55 B | ||
|
ResMed
RMD
|
$ 224.93 | 0.37 % | $ 32.9 B | ||
|
Retractable Technologies
RVP
|
$ 0.71 | 2.98 % | $ 21.3 M | ||
|
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | ||
|
STAAR Surgical Company
STAA
|
$ 20.96 | 3.71 % | $ 1.04 B | ||
|
STERIS plc
STE
|
$ 219.97 | 0.58 % | $ 21.7 B | ||
|
Stereotaxis
STXS
|
$ 1.88 | -0.53 % | $ 171 M | ||
|
Teleflex Incorporated
TFX
|
$ 115.04 | -2.35 % | $ 5.13 B | ||
|
Utah Medical Products
UTMD
|
$ 62.93 | -0.3 % | $ 204 M | ||
|
West Pharmaceutical Services
WST
|
$ 256.85 | 0.8 % | $ 18.6 B | ||
|
DENTSPLY SIRONA
XRAY
|
$ 11.64 | 0.09 % | $ 2.32 B | ||
|
AngioDynamics
ANGO
|
$ 9.84 | -4.56 % | $ 402 M | ||
|
Becton, Dickinson and Company
BDX
|
$ 155.32 | 0.52 % | $ 44.7 B | ||
|
Nephros
NEPH
|
$ 2.86 | -0.35 % | $ 29.7 M | ||
|
OraSure Technologies
OSUR
|
$ 3.08 | - | $ 226 M | ||
|
Repligen Corporation
RGEN
|
$ 116.95 | -0.7 % | $ 6.52 M |